Skip to main content

Advertisement

Table 1 Laboratory parameters

From: Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report

Point in time Laboratory parameter
   Therapy Hb (mmol/L) WBC (×109/L) PLT (×109/L) MCV (fL) Glu (mmol/L) CRP (mg/L) Sed (mm/hour)
2 months before referral None 5.52   132     
Referral None 4.41 2.9 163 77.3    
Diagnosis Nonea 4.03 3.7 191 77.4    
Post-diagnosis (wk) 1 Pred 4.34 3.9 220 79.7    
  2 Pred 4.41 4.0 201 80.0 14.6 27.0 67
  9 ADAb 5.96 2.7 142 79.5 14.3 25.0 41
  20 ADAc 5.46 3.3 179 78.0 5.8 33.0 105
  24 Noned 4.59 3.0 147 79.7 4.9 36.0 80
  31 Noned 4.41 3.8 174 80.9   34.0 92
  36 ADAe 4.10 3.7 152 84.3 5.9 30.0 50
  40 ADA 4.47 3.4 170 82.6 4.2 23.0 66
  45 ADA 5.03 3.6 177 83.4   9.0 63
  49 ADA 6.02 4.2 165 80.9 4.3 6.0 63
  53 ADA 5.96 3.7 146 77.2   4.0 14
  57 ADA 6.4 4.0 122 77.5 117 4.0 47
  1. aBegan prednisone at 20 mg/day;
  2. bsecond dose of adalimumab, tapered off prednisone;
  3. c7 doses of adalimumab, completely off prednisone;
  4. dpatient discontinued adalimumab for 9 weeks; adalimumab was restarted at post-diagnosis week 33;
  5. ethree doses of second course of adalimumab.
  6. Abbreviations: ADA, adalimumab; CRP, C-reactive protein; Glu, glucose; Hb, hemoglobin; MCV, mean cell volume; PLT, platelets; Pred, prednisone; Sed, sedimentation rate; WBC, white blood cells.